How we set specifications for impurities (including Genotoxic impurities) 24 May 2017 Elisabeth Kovacs, Apotex CSO Chemistry and Analytical Sci.
|
|
- Giles Ross
- 6 years ago
- Views:
Transcription
1 2017 AAM CMC Workshop How we set specifications for impurities (including Genotoxic impurities) 24 May 2017 Elisabeth Kovacs, Apotex CSO Chemistry and Analytical Sci.
2 The information within this presentation is based on the presenter's expertise and experience and represents the views of the presenter for the purposes of stimulating discussion at this workshop.
3 We all aim to do the right thing PAGE 3
4 We all aim to do the right thing Clinical Relevance Context, Connections and Collaboration FDA/PQRI Conference March 22, 2017 Sarah Pope Miksinski Director (acting), Office of Surveillance Director, Office of New Drug Products PAGE 4
5 Guidances available to industry 1. ICH Q 3 A&B: Impurities in Drug Substance and Drug Products-Identification and qualification threshold based on MDD or MDI 1. ICH Q3 C Residual Solvents- PDE 2. ICH3D- PDE 3. ICH M7- TTC, duration of treatment, structural similarity to API 4. FDA Guidance for ANDA ( API and Product) +RLD and USP 5. FDA Guidance on Refuse to Receive (RTR) (same as #5) PAGE 5
6 Clinically Relevant Specifications *Clinically Relevant Specifications ( CRS) Test Methods and acceptance criteria that identify and reject/accept drug product batches that are likely to perform inadequately / adequately in the indicated population (s) The CGMP regulations require that manufacturing processes be designed and controlled to assure that in-process materials and the finished product meet predetermined quality requirements and do so consistently and reliably.** Process controls address variability to assure quality of the product. Controls can consist of material analysis and equipment monitoring at significant processing points ( (c)). ** Predetermined Quality Requirement = Clinically Relevant Specifications *Richard (Rick) Lostritto, Ph.D CDER/FDA, PQRI, Conference on Evolving Product Quality, September 16-17, 2014, Bethesda, Maryland ** Guidance for Industry Process Validation: General Principles and Practices U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) Center for Veterinary Medicine (CVM) January 2011 Current Good Manufacturing Practices (CGMP) Revision 1 PAGE 6
7 ICH Guidelines Clinically relevant Specifications RLD Qualification ( impurities exceeding qualification threshold) Establishing Limits for impurities USP Qualification of Identified impurities Limits unidentified impurities to levels below the ICH level No Reporting Threshold Batch Data ( process capability) 5/23/2017 Progressing through the process limits tend to become increasingly tighter 7
8 Not Negotiable Patient Risk I bit of reality check Fact At the time Of filing Risk to Quality #1 #2 #3 #4 #5 #6 #7 #8 Limited no of batches (pilot) Limited stability data ( 6 Mo) Limited no of API batches No experience with scale up No experience with commercial process No information about RLD at expiry or the variability of the RLD API may be using a different synthetic route Product manufacturing process may be different than the RLD leading to different impurities ( degradation products) 5/23/2017 8
9 If the quality of a product confirmed by meeting the specification, than a lot depends on how we establish specifications Acceptance criteria based on process capability Acceptance criteria based on safety (Clinically Relevant Specifications) Potentially reject acceptable batches (failed batches, stability failures, recall, reduced shelf life) Specifications design based on product/ process understanding following scientific risk based principles linked to patient safety Impact on process capability (introduce variation at a level that has is not linked to quality) no value added Impact on process capability ( controls variability at levels relevant for product quality) Specifications can be too wide, to tight, or altogether irrelevant Cannot and do not improve the quality of a drug substance or product by tightening a specification This can only be done by changing the production process 5/23/2017 9
10 CRS vs Specifications established based on Process Capability Good Product, Good Process CRL UL: 0.5% Bad Process Bad Product? Batch data UL: 0.3% Batches 1->n PAGE 10
11 Considerations for RLD Limited number of batches available ( variability?) Typically at or around filing the RLD has years before expiring Do the levels observed in the RLD represent safety or process capability? Qualification? Metabolites Chiral Impurities PAGE 11
12 Lot# Other opportunities: Setting Specifications Solvent: methanol ICH Limit ( ICH Q3C): Option 1 (based on 10g/day intake) 3000 ppm Option 2: PDE (permitted daily exposure) 30mg/day Drug API: example Maximum daily intake in the example is: 7g/day Results ppm (Method Precision:6 samples) RSD: 6.6% SD= 198 ppm Calibration (6 injections): RSD 3.5% (SD=105ppm) Mean: 2640ppm SD: 259 ppm RSD: 10.9% Considerations for specifications: ICH option 1 : 3000 ppm ICH Option 2 (based on PDE): 4285 ppm PDE 30mg methanol : the maximum methanol content to ensure NMT 30mg daily exposure is 4285 ppm, based on the MDD ( maximum daily dose of example) of 7g/day. In other words, methanol content of NMT 4285ppm will correspond to NMT 30mg of methanol daily intake. Options for acceptance criteria: a) 3000 ppm* b) 0.3% c) 0.30% d) 4285 ppm (PDE) e) 0.4% f) 0.40% Acceptance Criteria Probability of being within spec % > USL NMT 3000 ppm 91.76% 8.24% (>8/100) NMT 0.30% 94.33% 5.67% (6/100) NMT 0.3% 99.95% 0.05% (1/10000) NMT 4285 ppm >99.99% 0.00% NMT 0.40% >99.99% 0.00% NMT 0.4% >99.99% 0.00% NA; (>PDE) Points to consider: An acceptance criteria of 3000 ppm will render a result of 3001 OOS An acceptance criteria of 0.3% will be considered in spec up to % An acceptance criteria of 0.30 will be considered in spec up to % An acceptance criteria 4285 ppm (PDE) will render a result of 4286 ppm as OOS An acceptance criteria of 0.4% will be considered in spec up to 4499 (>PDE) An acceptance criteria of 0.40% will be considered in spec up to % Using this mean and SD for a sample of size 1,000,000 random draws from a normal distribution the following can be predicted for future batches: 5/23/
13 Generic Product Synthetic route for API is often different from the RLD (at times unique) Different impurities Different form Different solvents Manufacturing Process for the Drug Product Different composition Different manufacturing process PAGE 13
14 Control Strategy Control Strategy - A planned set of controls, derived from current product and process understanding, that assures process performance and product quality. The controls can include parameters and attributes related to drug substance and drug product materials and components, facility and equipment operating conditions, in-process controls, finished product specifications, and the associated methods and frequency of monitoring and control. (ICH Q10) PAGE 14
15 Control Strategy for the Generic Product As a result the specifications for impurities can be quite different from the RLD It will require an analytical procedure designed and developed to control impurities that may not be present (or possible) in the RLD Some of the impurities in the RLD may not be present (or possible) in the generic product The USP method may not be suitable, will not detect, will overestimate or underestimated the new impurities ( equivalence?) The Drug Product while it meets ICH may not meet the USP limits using the USP analytical procedure PAGE 15
16 Generic Product and USP The USP specification for impurities ( analytical procedure and acceptance criteria) are representative of the monograph s sponsor s approved specifications. Are relevant to sponsor's Process ( API and Drug Product) Represent the sponsor s Process Capability The question that needs to be asked: 1. How USP specifications relate to Clinically Relevant Specifications? 2. How accurate are the following: A. USP limits always represent safety limits? B. USP specifications for impurities are always relevant for a generic product? C. The analytical procedure for impurities published in the USP is always appropriate for a generic product? PAGE 16
17 ICH Reporting Threshold- levels found below reporting threshold are not included in the calculation of total In Drug Product: Synthetic impurities not reported or included in the calculation of total impurities Impurities exceeding identification threshold can be identified and acceptance criteria established accordingly Matrix ( placebo Peaks) are excluded PAGE 17 Other Challenges in establishing specifications USP vs ICH USP No Reporting Threshold (occasional discard limit that only reflect method capability) All detected peaks are reported and included in total impurities No provision to identify impurities found to exceed identification threshold No provision to exclude matrix (placebo peaks)
18 Paths and processes developed by USP In cases where a product or an API may not meet the USP (current at that time) specifications (with the USP published procedure), USP developed procedures to allow compliance All paths however require FDA approval before it can be published and progress to official text Pending monographs Flexible monographs Interim Revision Procedure USP GC <476> and <1082> Organic Impurities in Drug Substances and Drug Products. 5/23/
19 Pending Monographs Three main stages for Pending Monographs: Draft (on USP website; 90-day comment) Authorized (by USP Expert Committee) Official in USP/NF Following publication in PF, the proposals remain in unofficial status until FDA s approval of the market application USP Guideline for Submitting Requests for Revision to USP NF General Information for All Submissions G Page 6 of 7 EFFECTIVE DATE 04/29/2016 by the sponsor. PAGE 19
20 Flexible Monographs (cont.) General Notices : Applicability of Test Procedures multiple procedures may be included in particular monographs specifically for the purpose of assuring the availability of an appropriate procedure for a particular product. In such cases, a labeling statement to indicate the appropriate application of the procedure(s) will be included in the monograph. A labeling statement is not required if Test 1 is used. PAGE 20
21 Interim Revision Announcements (IRAs) Interim Revision Announcements (IRAs) are published in Pharmacopeial Forum (PF) as proposed IRAs. After a 90-day notice and comment period and approval by the relevant USP Expert Committee, IRAs are posted as official text on the USP website, and are incorporated into the next available official publication (USP NF or Supplement). PAGE 21
22 USP GC<476> & <1086) Follows ICH Concepts Identification threshold Qualification threshold Limits based on MDD PAGE 22
23 RTR Guidance Pursuant to the enactment of the Generic Drug User Fee Amendments of 2012 (GDUFA),7 the Office of Generic Drugs (OGD) is tasked with a number of activities, including the development of enhanced refusal to receive standards for ANDAs and other related submissions by the end of year 1 of the program. Enhanced RTR standards are important because the practice of submitting an ANDA that is not sufficiently complete to permit a substantive review, which then is repaired via several cycles of applicant resubmission and FDA response, is inherently inefficient and a drain on FDA resources. 5/23/
24 Closing Remarks The agency is moving toward Clinically Relevant Specifications and guiding industry to consider risk in the context of clinical performance Encourage industry to use science and risk considerations when establishing specifications that should lead to tests and acceptance criteria based on clinical relevance and not on process capability and/or batch data Give industry opportunities to work in the framework of the USP processes that rely on FDA review and approval before changing and/or progressing to official text. PAGE 24
25 Closing Remarks (cont.) Understand the challenges industry faces when expected to commit to compendia limits when these do not represent safety therefore are not clinically relevant but rather represent the monograph s sponsor process capability Industry would appreciate a more in-depth evaluation during the technical review stage and more flexibility over the enhanced assessment which occurs at filing. Collaborate with industry to move from what appears to be a one measure fits all approach to a more science and risk based process for establishing limits for impurities in products that reflects the innovation in FDA s regulatory approaches. PAGE 25
26 A Generic Industry Perspective on Establishing Impurity Limits And a Corresponding Control Strategy An applicant is not expected to tighten the limits based on process capability, provided that the elemental impurities in drug products do not exceed the PDE ( ICH Q3D) An applicant is not expected to tighten limits for impurities based on process capability provided that the impurities in drug products do not exceed the qualified levels Is this enlightened philosophy consistently followed by FDA re: organic impurity limits in ANDAs? Nicholas Cappuccino, PhD Vice-President, Head of Quality and Scientific Affairs, Dr. Reddy s Laboratories, Inc GPhA CMC Workshop October 2016, Bethesda Marriott 5/23/
27 A Generic Industry Perspective on Establishing Impurity Limits And a Corresponding Control Strategy An applicant is not expected to tighten the limits based on process capability, provided that the elemental impurities in drug products do not exceed the PDE ( ICH Q3D) An applicant is not expected to tighten limits for impurities based on process capability provided that the impurities in drug products do not exceed the qualified levels* ICH Q9: PRINCIPLES OF QUALITY RISK MANAGEMENT Two primary principles of quality risk management are: The evaluation of the risk to quality should be based on scientific knowledge and ultimately link to the protection of the patient; and The level of effort, formality and documentation of the quality risk management process should be commensurate with the level of risk. *Nicholas Cappuccino, PhD Vice-President, Head of Quality and Scientific Affairs, Dr. Reddy s Laboratories, Inc GPhA CMC Workshop October 2016, Bethesda Marriott 5/23/
28 CRS vs Specifications established based on Process Capability Good Product, Good Process CRL UL: 0.5% Bad Process Bad Product? Batch data UL: 0.3% Batches 1->n PAGE 28
29 CRS vs Specifications established based on Process Capability Good Product, Good Process CRL UL: 0.5% Batches 1->n PAGE 29
30 We all aim to do the right thing PAGE 30
31 Thank you for your attention Any Questions? Elisabeth Kovacs, Apotex, 150 Signet Drive Toronto Ontario, Canada, M9L 1T9 PAGE 31
Regulatory expectations on impurities in drug substances - Pavia, October 2, Luisa Torchio Euticals SpA
Regulatory expectations on impurities in drug substances - Pavia, October 2, 2015 Luisa Torchio Euticals SpA An Impurity is defined as any substance or element present in a drug substance (DS) that is
More informationStarting Material Selection for Type II Drug Master Files
Starting Material Selection for Type II Drug Master Files Ronald S. Michalak Quality Assessment Lead (Acting), Division of Lifecycle API Office of New Drug Products, OPQ/CDER/ FDA CDER Reorganization Office
More informationBRIEFING. . Over time, 466 may be used less frequently and may be withdrawn.
Page 1 of 13 BRIEFING 1086 USP 37 page 828. As part of an ongoing monograph modernization initiative, the United States Pharmacopeial Convention (USP) is updating this general chapter, 1086 Impurities
More informationAPI Testing Requirements to Support the EI Risk Assessment. Elisabeth Corbett Associate Director, GRS-CMC, Bristol-Myers Squibb November 9, 2016
API Testing Requirements to Support the EI Risk Assessment Elisabeth Corbett Associate Director, GRS-CMC, Bristol-Myers Squibb November 9, 2016 Agenda Background Review of ICH Q3D Risk Assessment Principles
More informationFlexible and Pending Monographs
Flexible and Pending Monographs USP Approaches to Accommodate Multiple Approved Products Doreen McDonald Senior National Account Manager U.S. Pharmacopeial Convention Flexible Monographs: Background From
More informationGuidance for Industry
Guidance for Industry ANDAs: Impurities in Drug Products DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document should
More informationEvolution of the CMC Review - ANDAs
Evolution of the CMC Review - ANDAs Susan Rosencrance, Ph.D. Director (Acting), Office of Lifecycle Drug Products Office of Pharmaceutical Quality FDA Center for Drug Evaluation and Research October 6,
More informationOverview of USP Activities and How to Get Involved
Overview of USP Activities and How to Get Involved Ravi Ravichandran, Ph.D. Principal Scientific Liaison, Chemical Medicines United States Pharmacopeia Outline Introduction to the USP USP Standard Setting
More informationClinically Relevant Dissolution Specifications: FDA Perspective and Initiatives
Clinically Relevant Dissolution Specifications: FDA Perspective and Initiatives 2015 GPhA CMC Workshop June 10, 2015 Paul Seo, Ph.D. Division Director (Acting) OPQ/ONDP/Division of Biopharmaceutics 1 Outline
More informationRegulatory Starting Materials An FDA Perspective
Regulatory Starting Materials An FDA Perspective Kasturi Srinivasachar Branch Chief (Acting), New Drug API Division Office of New Drug Products, OPQ/CDER/ FDA 1 CDER Reorganization Office of Pharmaceutical
More informationGPhA Fall Technical Conference Nov 2-5, 2015 Bethesda, MD ICH M7 Guidance Overview and Current FDA Perspectives
GPhA Fall Technical Conference Nov 2-5, 2015 Bethesda, MD ICH M7 Guidance Overview and Current FDA Perspectives Stephen Miller, Ph.D. CMC-Lead; Office of New Drug Products Office of Pharmaceutical Quality
More informationIMPURITIES IN NEW DRUG PRODUCTS
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE IMPURITIES IN NEW DRUG PRODUCTS Recommended for
More informationPHARMACEUTICAL TESTING
WHITEHOUSE, NJ PHARMACEUTICAL TESTING Pharmaceutical Expertise for GMP & CMC Testing Our Pharmaceutical Expertise With more than 20 years of experience in a variety of industries, our Whitehouse, New Jersey
More informationNew Drug Product Impurities
Title Page Image - with courtesy of the FDA CDER original web site at www. cder.fda.gov/ New Drug Product Impurities IAGIM Scientific Committee Block JD; Holmann E ; West P NEW DRAFT GUIDANCE FDA Viewpoint
More informationDerivation and Justification of Safety Thresholds
Derivation and Justification of Safety Thresholds Douglas J. Ball, MS, DABT Chair, PQRI L&E Toxicology Subgroup Research Fellow, Safety Sciences - Pfizer, Inc. Agenda Basic Definitions Current Regulatory
More informationFurther Stability Considerations
Further Stability Considerations Radhika Rajagopalan, Ph.D., Team Leader Chemistry Division 2 Office of Generic Drugs, FDA FDA-GPhA Workshop June 4, 2013 1 Agenda Common considerations Q1D Bracketing and
More informationFDA S GUIDANCE FOR INDUSTRY ANDAS: STABILITY TESTING OF DRUG SUBSTANCES AND PRODUCTS
FDA S GUIDANCE FOR INDUSTRY ANDAS: STABILITY TESTING OF DRUG SUBSTANCES AND PRODUCTS 02-December-2014 San Diego, CA Kim Huynh-Ba Executive Director PHARMALYTIK Kim.huynhba@pharmalytik.com Overview Stability
More informationCANADA (HEALTH CANADA)
1 GMP GAZETTE TM May 2016 HPFBI CANADA (HEALTH CANADA) No updates NNHPD NHPs Final Monograph for Antiseptic Skin Cleanser Who`s Affected? Companies seeking NPN or DIN for topical antiseptic hand cleansers
More informationImplementation of the ICH Q3D guideline in the Ph. Eur.
Implementation of the ICH Q3D guideline in the Ph. Eur. PQRI/USP Workshop, USP Meeting center 9-10 November 2016 Bruno Spieldenner, Ph. Eur. division, EDQM Elemental impurities in the Ph. Eur. A (r)evolution
More informationRole of USP Monographs and. General Chapters. Steve Zigler, Ph.D.
Role of USP Monographs and General Chapters Steve Zigler, Ph.D. Siemens PETNET Solutions USP Disclosure I have served as a USP volunteer in the area of PET drugs for 15 years Member of various Expert Committees
More informationAPI Selection of Starting Materials Impact on First Cycle Approval
API Selection of Starting Materials Impact on First Cycle Approval Presented by Aloka Srinivasan, Ph.D. Vice President, Regulatory Affairs May 24, 2017 Trends in Selection of Regulatory Starting Materials
More informationICH Q3D Guideline Impact on the Users: Perspective of a Finished Product Manufacturer John Glennon
ICH Q3D Guideline Impact on the Users: Perspective of a Finished Product Manufacturer John Glennon 9 November 2016 Disclaimer The views and opinions expressed in this presentation are those of the author
More informationCDER 2016 Actions and 2017 Priorities. Richard Moscicki Deputy Center Director for Science Operations, CDER, FDA
CDER 2016 Actions and 2017 Priorities Richard Moscicki Deputy Center Director for Science Operations, CDER, FDA Disclosure My comments today are mine and do not necessarily represent the views of the US
More informationReference Standard Characterization. Steve Lane. General Manager, NSF Reference Standards.
Reference Standard Characterization Steve Lane General Manager, NSF Reference Standards www.nsf-rs.org Regulatory Bodies will require that an Excipient: Be safe in the amount or dose used Meet applicable
More informationICH Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management
ICH Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management Keith O. Webber, Ph.D. Sr. Director, Global Regulator Affairs Rx Perrigo Company, plc Q U A L I T Y A F F
More informationIdentifying and Controlling CPPs and CMAs
March 2018, BioPharm International Publication Identifying and Controlling CPPs and CMAs Thomas A. Little Ph.D. 2/22/2018 President/CEO Thomas A. Little Consulting, BioAssay Sciences 12401 N Wildflower
More informationQuestions and answers on the 'Guideline on the limits of genotoxic impurities'
23 September 2010 EMA/CHMP/SWP/431994/2007 Rev. 3 Committee for Medicinal Products for Human Use (CHMP) Safety Working Party (SWP) Questions and answers on the 'Guideline on the limits of genotoxic impurities'
More informationThe Role of Chemists in the FDA Drug Approval Process
The Role of Chemists in the FDA Drug Approval Process 231 st ACS National Meeting Atlanta, GA M. Scott Furness, Ph.D. March 26, 2006 Introduction Presentation Outline FDA Organization CDER Organization
More informationBest Practices and Application of GMPs for Small Molecule Drugs in Early Development IQ Workshop, Feb 4-5, 2014, Washington, D.C.
Best Practices and Application of GMPs for Small Molecule Drugs in Early Development IQ Workshop, Feb 4-5, 2014, Washington, D.C. Specifications Breakout Session 2 Pete Yehl and Mike Coutant, moderators
More informationRisk Management: FDA and Industry Experience. Dan Snider, Ph.D Vice President Morgantown RD Mylan Pharmaceuticals Inc.
Risk Management: FDA and Industry Experience Dan Snider, Ph.D Vice President Morgantown RD Mylan Pharmaceuticals Inc. Disclaimer This presentation contains a summary of the opinion and perspective from
More informationIMPURITIES. Antony Fake API Focal Point, PQTm WHO PREQUALIFICATION TEAM MEDICINES
IMPURITIES Antony Fake API Focal Point, PQTm IMPURITIES PQTm Training Copenhagen, May 2016 1 Introduction This presentation is made with reference to the preparation of an API. This is because the API
More informationAPI Stability Protocols and. Chris Byrne Tasmanian Alkaloids
API Stability Protocols and Evaluations Chris Byrne Tasmanian Alkaloids API Stability Overview APIs = 100% pure Limited (if any) degradation No interactions with other agents in drug products Less likelihood
More informationLatest USP Initiatives: Monographs, General Chapters, and Compounding
Latest USP Initiatives: Monographs, General Chapters, and Compounding Jim Ponto, MS, RPh, BCNP Disclosures Volunteer member on several USP Expert Committees and Expert Panels associated with radiopharmaceutical
More informationDrug Substance Review in the Office of Pharmaceutical Quality
Drug Substance Review in the Office of Pharmaceutical Quality GPhA 2015 CMC Workshop Bethesda, MD June 9, 2015 M. Scott Furness, Ph.D. Deputy Director, Office of New Drug Products Office of Pharmaceutical
More informationOctober 10, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852
October 10, 2017 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Docket No. FDA 2017 D 2802: Chemistry, Manufacturing, and Controls
More informationEarly Development Best Practices for Stability- Regulatory Perspective
Early Development Best Practices for Stability- Regulatory Perspective IQ Workshop, Feb. 4-5, 2014, Washington, D.C. Ramesh Sood, Ph.D. Division Director (Acting) Office of New Drug Quality Assessment
More informationAnalytical Methods Development and Validation
Understanding and Implementing Efficient Analytical Methods Development and Validation Jay Breaux, Kevin Jones, and Pierre Boulas Analytical methods development and validation play important roles in the
More informationContinuous Manufacturing Achieving the Vision of Modernizing Pharmaceutical Manufacturing
Continuous Manufacturing Achieving the Vision of Modernizing Pharmaceutical Manufacturing FDA-AIChE Workshop on Adopting Continuous Manufacturing February 29 March 1, 2016 Rapti Madurawe, Ph.D. Acting
More informationHot Topics in Drug Product Process Validation: A Reviewer s Perspective
Hot Topics in Drug Product Process Validation: A Reviewer s Perspective Colleen Thomas, Ph.D. Quality Assessment Lead (Acting) FDA/CDER/OPQ/OPF Division of Microbiology Assessment CASSS CMC Strategy Forum
More informationReplacing Analytical Methods for Release and Stability Testing CBER Perspective
Replacing Analytical Methods for Release and Stability Testing CBER Perspective Presentation at the CMC Strategy Forum January 27, 2014 Lokesh Bhattacharyya Chief, Lab of Analytical Chemistry and Blood
More information"NOT FOR IMPLEMENTATION" GUIDANCE FOR INDUSTRY
"NOT FOR IMPLEMENTATION" GUIDANCE FOR INDUSTRY Modified Release Solid Oral Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls, In Vitro Dissolution Testing, and In Vivo
More informationGuidance for Industry
Guidance for Industry Heparin for Drug and Medical Device Use: Monitoring Crude Heparin for Quality DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions
More informationInvestigating OOS for Finished Product on the Stability Program. Presented by: Nicole Chang, QA Manager, Apotex Pty Ltd
Investigating OOS for Finished Product on the Stability Program Presented by: Nicole Chang, QA Manager, Apotex Pty Ltd Overview 1. Requirements of the commercial stability program 2. Out of Specification
More informationCase study 2: Parenteral Drug Product
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 Purpose of Case Study 2: The following case study provides one example of a summary of an elemental impurities risk
More informationIndustry Experience: Early Collaboration with FDA on Combination Products. Kristi Kistner, Amgen Inc. CMC Strategy Form January 26, 2015
Industry Experience: Early Collaboration with FDA on Combination Products Kristi Kistner, Amgen Inc. CMC Strategy Form January 26, 2015 Collaboration is working together to achieve shared goals Given the
More informationUSP Chapter 823 USP 32 (old) vs. USP 35 (new)
USP Chapter 823 USP 32 (old) vs. USP 35 (new) Sally W. Schwarz, MS, BCNP Research Associate Professor of Radiology Washington University School of Medicine St. Louis, MO Why USP Chapter ? FDA has
More informationfor IND and RDRC Regulated PET Compounding
Overview of USP Chapter for IND and RDRC Regulated PET Compounding Distributed Manufacturing of PET Radiopharmaceuticals for Multi-Center Clinical Trials SNM, Annual Meeting Toronto, Ontario, Canada
More informationFuture of Pharmaceutical Quality and the Path to Get There
Future of Pharmaceutical Quality and the Path to Get There Lawrence Yu, Ph.D. Deputy Director, Office of Pharmaceutical Quality FDA Center for Drug Evaluation and Research 3rd PQRI/FDA Conference on Advancing
More informationUpdates on Quality Metrics - Industry Perspectives Dan Snider Vice President, Research and Development Mylan Inc.
GPhA/FDA FALL TECHNICAL CONFERENCE Updates on Quality Metrics - Industry Perspectives Dan Snider Vice President, Research and Development Mylan Inc. Disclaimer This presentation contains a summary of the
More informationManaging Quality in Pharmaceutical Industry Using Six Sigma. Edited by Mahmoud Farouk Moussa TQM, CSSBB, MBA
Managing Quality in Pharmaceutical Industry Using Six Sigma Edited by Mahmoud Farouk Moussa TQM, CSSBB, MBA Outlines Pharmaceutical Manufacturing Process and Drug Product Quality. Process Excellence Approach
More informationVariation Regulations (EU)
Variation Regulations (EU) Headlines of the Update APIC c view Hilde Vanneste APIC Task Force leader Hilde.Vanneste@its.jnj.com 1 Content Scope of regulation: Type of procedures and hence 2 strands Current
More informationExtractables and leachables: An Introduction
Extractables and leachables: An Introduction Tim Hulme Smithers Rapra THulme@smithers.com 44(0)1939 252 418 1 Extractables and leachables: An Introduction Tim Hulme Smithers Rapra thulme@smithers.com 2
More informationHarmonizing FDA Regulation and the Practice of Pharmacy: Challenges and Opportunities. Plus an update on PET Drug User Fees
Harmonizing FDA Regulation and the Practice of Pharmacy: Challenges and Opportunities Plus an update on PET Drug User Fees Michael Nazerias - Vice President, RA/QA PETNET Solutions, Inc. (a Siemens Company)
More informationCDER /OPQ Office of Surveillance Quality Metrics in Surveillance
CDER /OPQ Office of Surveillance Quality Metrics in Surveillance Russell Wesdyk Acting Director Office of Surveillance Office of Surveillance Goals Builds from the shared vision A maximally efficient,
More informationElemental Impurities: An Industry Perspective
Elemental Impurities: An Industry Perspective Ernest Parente, PhD Mallinckrodt Pharmaceuticals May 17, 2016 2016 GPhA CMC Workshop Overview Risk Assessment The Supplier Interface The Contractor Interface
More informationCOMMERCIAL PRODUCT STABILITY
COMMERCIAL PRODUCT STABILITY Being Responsible for your Tweener, Senior Citizen and Hospice Stage Products Melissa Lambert Global Head Stability in Quality & Compliance Management, R&D Director Quality
More informationá232ñ ELEMENTAL IMPURITIES LIMITS
First Supplement to USP 40 NF 35 Chemical Tests / á232ñ al Impurities Limits 8065 Standard Solution Table 10 (Continued) of Neu5Ac after Labeling (mm) of Neu5Gc after Labeling (mm) 4 0.2 0.01 5 0.4 0.02
More information22 January Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, rm Rockville, MD 20852
22 January 2009 Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, rm. 1061 Rockville, MD 20852 SUBMISSION OF COMMENTS, DOCKET NO. FDA-2008-D-0559 Dear Sir or Madam:
More informationLaboratory OOS Investigations The Missing Link
Laboratory OOS Investigations The Missing Link India Pharmaceutical Alliance Carmelo Rosa, Psy.D Director Division of Drug Quality I November 6-17, 2017 Indian Pharmaceutical Alliance DISCLAIMER: The views
More informationCEP submission: How to prepare a New Application?
CEP submission: How to prepare a New Application? Nathalie Vicente Certification of Substances Division Summary How to prepare a New Application? Requirements for a new CEP application Content of the dossier
More informationHow to implement ICH Q3D of elemental impurities in 5 steps
How to implement ICH Q3D of elemental impurities in 5 steps Directive ICH Q3D aims to limit the presence of potentially toxic elemental impurities (also known as heavy metals) in pharmaceutical products
More informationLeachable and Extractable Testing
Leachable and Extractable Testing A Primer on Regulations and Methods As presented to By: Anthony Grilli, MS General Manager SGS LSS NJ Laboratory 973 244 2435 Anthony.Grilli@SGS.com Summary Why perform
More informationIVT Laboratory Week Jerry Lanese. Ph.D. The Lanese Group, Inc The Lanese Group, Inc.
IVT Laboratory Week-2015 Jerry Lanese Ph.D. The Lanese Group, Inc. 1 Name Job What brought you here. 2 FDA interest in Quality Metrics What are Quality Metrics Quality metrics FDA will request The impact
More informationCurrent Topics For Sterile Generic Drug Products
Current Topics For Sterile Generic Drug Products Marla Stevens-Riley, Ph.D. Team Leader Division of Microbiology for ANDA Review FDA/CDER GPHA CMC Workshop June 4, 2014 Disclaimer Opinions expressed in
More informationQbD implementation in Generic Industry: Overview and Case-Study
QbD implementation in Generic Industry: Overview and Case-Study Inna Ben-Anat, QbD Strategy Leader, Teva Pharmaceuticals IFPAC JAN 2013 R&D Three Core Components of QbD and Generic Industry: How Do They
More informationSTANDARD OPERATING PROCEDURES. Handling and working with Analytical Standards
Page: 1 of 6 1.Purpose The purpose of this Standard Operating Procedure is to establish a standardized procedure of using United States Pharmacopoeia (USP) standards, detailing the procedure of qualification,
More informationHow to Identify Critical Quality Attributes and Critical Process Parameters
How to Identify Critical Quality Attributes and Critical Process Parameters Jennifer Maguire, Ph.D. Daniel Peng, Ph.D. Office of Process and Facility (OPF) OPQ/CDER/FDA FDA/PQRI 2 nd Conference North Bethesda,
More informationIndustry Perspective on Manufacturing in Early Development
Industry Perspective on Manufacturing in Early Development IQ Workshop, Feb 4-5, 2014, Washington, D.C. Eric Schmitt AbbVie IQ Drug Product Manufacturing Working Group August 2012 issue of Pharmaceutical
More informationMultiple stakeholders; one objective. Atypical Actives Industry Perspective. USP Excipients Stakeholder Forum November 29, 2017
Atypical Actives Industry Perspective USP Excipients Stakeholder Forum November 29, 2017 Multiple stakeholders; one objective. Priscilla Zawislak Chair, IPEC-Americas pzawislak@dow.com International Pharmaceutical
More informationGDUFA RESEARCH AND REGULATORY INITIATIVES FOR COMPLEX TOPICAL PRODUCTS
GDUFA RESEARCH AND REGULATORY INITIATIVES FOR COMPLEX TOPICAL PRODUCTS 4 th Annual Symposium on Development of Generics & 505(b)(2) Achieving Access to Complex Drug Products: Integrating Scientific and
More informationRegulatory Review Considerations of Drug-Linker Quality in ADCs
Regulatory Review Considerations of Drug-Linker Quality in ADCs Xiao Hong Chen, Ph.D. Acting Quality Assessment Lead Division of New Drug Products I, Branch II ONDP/OPQ/CDER/FDA Outlines ADC IND submissions
More informationSession 7 Clinical Trial Assessment Bioequivalence Studies
L1 Session 7 Clinical Trial Assessment Bioequivalence Studies Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager, Clinical Group I Office
More informationCGMP for Phase 1 INDs
CGMP for Phase 1 INDs Laurie P. Norwood Deputy Director Division of Manufacturing and Product Quality Office of Compliance and Biologics Quality Center for Biologics Evaluation and Research 1 Overview
More informationUSA Proprietary Name Review Process
USA Proprietary Name Review Process Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) Office of Surveillance and Epidemiology (OSE) Division of Medication Errors and Prevention
More informationBench to Bedside - The Roadmap Chemistry, Manufacturing, and Controls Issues in Radiopharmaceutical Applications
Bench to Bedside - The Roadmap Chemistry, Manufacturing, and Controls Issues in Radiopharmaceutical Applications 55 th Annual Meeting of the Society of Nuclear Medicine New Orleans, LA, June 14-18, 18,
More informationGuideline on setting specifications for related impurities in antibiotics
1 2 3 4 14 July 2010 EMA/CHMP/CVMP/QWP/199250/2009 Committee for Medicinal Products for Human Use (CHMP) / Committee for Medicinal Products for Veterinary Use (CVMP) 5 6 7 Guideline on setting specifications
More informationCLEANING VALIDATION WITH RISK ASSESSMENT
CLEANING VALIDATION WITH RISK ASSESSMENT Bangkok, Thailand July 26 2017 Jairaj (Jai) Mehta, Consultant, Promoting the Quality of Medicines 2016. ALL RIGHTS RESERVED. Presentation Outline: Cleaning Validation
More informationA.1 Contents file 4 to 5 A.1 (1)
Contents file 4 to 5 Contents file 4 to 5 A Information Contents file 4 to 5 A.2 Index file 4 to 5 A.3 List of Abbreviations A.4 Glossary A.5 Adress-Register A.6 References B Japanese Regulations B.1 MHW
More informationCurrent Features of USFDA and EMA Process Validation Guidance
Human Journals Review Article April 2016 Vol.:6, Issue:1 All rights are reserved by Patwekar S.L et al. Current Features of USFDA and EMA Process Validation Guidance Keywords: Pharmaceutical validation,
More informationGUIDELINE FOR THE STABILITY TESTING
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 GUIDELINE FOR THE STABILITY TESTING OF NON-PRESCRIPTION (OTC)
More informationPharmaceutical Development (Drug Substance & Drug Product) for Visceral Leishmaniasis candidate DNDI-6148
Request for Proposal Pharmaceutical Development (Drug Substance & Drug Product) for Visceral Leishmaniasis candidate DNDI-6148 Dated: October 12 th 2015 Page 1 Table of Contents 1. PURPOSE... 3 2. RFP
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Page 1 of 8 Inspections, Compliance, Enforcement, and Criminal Investigations Lupin Limited 5/7/09 Department of Health and Human Services Public Health Service Food and Drug Administration CENTER FOR
More informationBMS Experience with the FDA-EMA QbD/PAT Joint Pilot Ambarish K. Singh, PhD Director, Global Regulatory Sciences-CMC Bristol-Myers Squibb Company
BMS Experience with the FDA-EMA QbD/PAT Joint Pilot Ambarish K. Singh, PhD Director, Global Regulatory Sciences-CMC Bristol-Myers Squibb Company FDA/PQRI Conference on Evolving Product Quality September
More informationPROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7:NON-STERILE PROCESS VALIDATION
1 Working document QAS/13.527/Rev.2 August 2014 RESTRICTED 2 3 4 5 6 7 8 9 10 PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7:NON-STERILE PROCESS
More informationPre-Approval Inspections for Drug Products
Pre-Approval Inspections for Drug Products FDA Small Business Regulatory Education for Industry Conference June 20, 2013 H.L. Jamillah Selby Consumer Safety Officer FDA, Dallas District Office Presentation
More informationWHO GUIDELINE Stability testing of active pharmaceutical ingredients and finished pharmaceutical products
WHO GUIDELINE Stability testing of active pharmaceutical ingredients and finished pharmaceutical products 1. Introduction 1.1 Objectives of these guidelines 1.2 Scope of these guidelines 1.3 General principles
More informationImplementation of ICH Q3D in the Certification Procedure
LS/CB PUBLIC DOCUMENT (LEVEL 1) PA/PH/CEP (16) 23 Strasbourg, August 2016 Certification of suitability to the Monographs of the European Pharmacopoeia Implementation of ICH Q3D in the Certification Procedure
More informationProposed New USP General Chapter: The Analytical Procedure Lifecycle 1220
Page 1 of 9 STIMULI TO THE REVISION PROCESS Stimuli articles do not necessarily reflect the policies of the USPC or the USP Council of Experts Proposed New USP General Chapter: The Analytical Procedure
More informationExamples of regulatory expectations for analytical characterization and testing
Examples of regulatory expectations for analytical characterization and testing AT Europe 2016, 18 March 2016 Vicki Venizelos Quality RA B.V. Leiden, the Netherlands Overview What are the regulatory expectations?
More informationParticulate Matter and Visual Inspection: Industry Trends 2015
Particulate Matter and Visual Inspection: Industry Trends 2015 John G. Shabushnig, Ph.D. Insight Pharma Consulting, LLC November 2015 Agenda FDA Recalls and 483 Observations Industry Benchmarking Survey
More informationQ10 PHARMACEUTICAL QUALITY SYSTEM
Q10 PHARMACEUTICAL QUALITY SYSTEM This draft guidance, when finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights
More informationDaniel Y. Peng, Ph.D.
Using Control Charts to Evaluate Process Variability Daniel Y. Peng, Ph.D. Quality Assessment Lead Office of Process and Facility (OPF) OPQ/CDER/FDA PQRI 205 Annual Meeting North Bethesda, Maryland October
More informationContinuous Pharmaceutical Manufacturing: CGMP, Process Validation, and Inspectional Considerations for Implementation
Continuous Pharmaceutical Manufacturing: CGMP, Process Validation, and Inspectional Considerations for Implementation Christina Capacci-Daniel, Ph.D. Consumer Safety Officer / Acting Quality Assessment
More informationResponding to an FDA 483
Responding to an FDA 483 Jim Melancon VP, Associate General Counsel BioScrip, Inc. Marc Stranz, PharmD Healthcare Consultant Disclosure The speakers declare no conflicts of interest or financial interest
More informationConnection Between Quality, Safety, and Efficacy
PQRI-FDA Workshop on Process Drift Bethesda, Maryland Connection Between Quality, Safety, and Efficacy Roger L. Williams, M.D. United States Pharmacopeial Convention December 1 3, 2010 Topics Overview
More informationSTIMULI TO THE REVISION PROCESS
Page 1 of 6 STIMULI TO THE REVISION PROCESS Stimuli articles do not necessarily reflect the policies of the USPC or the USP Council of Experts USP's Nomenclature Initiatives Angela G. Long, M.S.; Andrzej
More informationI. DEFINITION This training under Kilimanjaro School of Pharmacy Industrial Pharmacy Teaching Unit (IPTU) is an Advanced Training Program in Drug Development, Drug Manufacturing, Regulatory & Quality Compliance.
More informationOverview of FDA Regulations and Guidance Documents related to PET Drug Chemistry. Steve Zigler, Ph.D. Siemens PETNET Solutions
Overview of FDA Regulations and Guidance Documents related to PET Drug Chemistry Steve Zigler, Ph.D. Siemens PETNET Solutions Employee of Siemens-PETNET Solutions I will not discuss investigational agents,
More informationFDA Process Validation
Page 1 of 5 Published on Controlled Environments Magazine (http://www.cemag.us) Home > FDA Process Validation FDA Process Validation Wai Wong Working with the New 2011 Guidelines. In January 2011, the
More information